AUGMENTIN SAFETY INFORMATION

1

Contraindicated in patients with known hypersensitivity to ß-lactam antibiotics (penicillins & cephalosporins).

Gastrointestinal disturbances are common. Prolonged use may result in overgrowth of non-susceptible organisms.

Adverse Reactions:

Adults

Very common Diarrhoea

Common Nausea, vomiting, Mucocutaneous candidiasis

Children

Common Diarrhoea, nausea, vomiting

Please refer to the full prescribing information for further details

Reference: 1. Prescribing information Augmentin BD tablet 1G, 625mg IPIv16

For Nigerian Healthcare Professionals Only

Marketing Authorisation Holder: Fensyl MHP Consulting Ltd, 49 Kofo Abayomi Avenue, Lagos, Nigeria Augmentin

Tabs manufactured by GSK WORTHING, UNITED KINGDOM

To report an adverse event, send an email to pm.safety@gsk.com.

©2026 GSK group of companies or its licensor.

GlaxoSmithKline Export Limited, at 79 New Oxford Street, London, WC1A 1DG, UK.

Trade marks are owned by or licensed to the GlaxoSmithKline group of companies

PM-NG-ACA-BNNR-260002 Date of preparation: March 2026

Promotional material | For Nigerian healthcare professionals only